Smith & Nephew to Acquire Osiris Therapeutics

Paul, Weiss is representing UK-based medical technology business Smith & Nephew plc in its all-cash $660 million acquisition of U.S.-based regenerative medicine maker Osiris Therapeutics, Inc. The deal values U.S.-based Osiris at $19.00 per share. The transaction is expected to close in the second quarter of 2019.

The Paul, Weiss team includes, among others, corporate partners Scott Barshay and counsel Patricia Vaz de Almeida; employee benefits partner Lawrence Witdorchic; tax partners Patrick Karsnitz and Jeffrey Samuels and counsel Alyssa Wolpin; intellectual property partner Claudine Meredith-Goujon; real estate partner Mitchell Berg; antitrust counsel Marta Kelly; international trade counsel Richard Elliott; environmental counsel William O’Brien; and litigation partner Daniel Toal.